Next Article in Journal
New Cleft-like Molecules and Macrocycles from Phosphonate Substituted Spirobisindanol
Next Article in Special Issue
Synthesis and Total 1H- and 13C-NMR Assignment of Cephem Derivatives for Use in ADEPT Approaches
Previous Article in Journal
Docking Studies and Anti-inflammatory Activity of β-Hydroxy-β-arylpropanoic Acids
Previous Article in Special Issue
Prodrugs for Amines
Molecules 2008, 13(3), 616-677; doi:10.3390/molecules13030616

Prodrugs for the Treatment of Neglected Diseases

1,* , 2,* , 1,2, 2, 2, 1, 1, 1 and 1
1 Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil 2 LAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S,Cidade Universitária,Brazil
* Authors to whom correspondence should be addressed.
Received: 11 January 2008 / Revised: 12 March 2008 / Accepted: 12 March 2008 / Published: 19 March 2008
(This article belongs to the Special Issue Prodrugs)


Recently, World Health Organization (WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas’ disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis.
Keywords: Tropical neglected diseases; Prodrug design; American trypanosomisasis; African trypanosomiasis; Malaria; Sickle cell disease; Tuberculosis; Leishmaniasis; Schistosomiasis. Tropical neglected diseases; Prodrug design; American trypanosomisasis; African trypanosomiasis; Malaria; Sickle cell disease; Tuberculosis; Leishmaniasis; Schistosomiasis.
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Chung, M.C.; Ferreira, E.I.; Santos, J.L.; Giarolla, J.; Rando, D.G.; Almeida, A.E.; Bosquesi, P.L.; Menegon, R.F.; Blau, L. Prodrugs for the Treatment of Neglected Diseases. Molecules 2008, 13, 616-677.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert